HROW · Harrow, Inc. · Stock research

Current Thesis

Two weeks past the Q2 print, nothing has arrived that resolves the arithmetic the print created. Revenue of $70.661M on 2026-08-10 landed below the company's own $71–81M guidance floor, and FY2026 guidance was reaffirmed anyway at $350–365M revenue with $80–100M adjusted EBITDA. Against H1 revenue of $114.9M, that leaves $235–250M for the back half — INFERRED from the two disclosed figures, not a company statement — while adjusted EBITDA has to travel from Q1 $(12.7)M and Q2 $(1.2)M to a guided full-year $80–100M. The equity is pricing that swing against a balance sheet carrying $292.4M loans payable net, $83.9M cash and $14.8M of stockholders' equity at 2026-06-30, with $30M more due at the TYRVAYA close.

What is new since the last update is narrow and clinical. On 2026-08-20 Harrow released a prospective, randomized, contralateral-eye study in 50 patients (100 eyes) undergoing same-day bilateral intravitreal injections: patients reported approximately 58% less overall discomfort in the IHEEZO-treated eye than in the fellow eye given proparacaine 0.5%, statistically significant at all four post-injection assessments (all p≤0.048). Both eyes received 2% lidocaine-soaked pledgets first, so the comparison is IHEEZO versus a topical drop on top of a common base. That supports the retina channel behind IHEEZO's 65,477 Q2 units (+44% sequentially, +34% YoY), and it is a 50-patient patient-reported-comfort study — no label change, no reimbursement decision.

The narrative is maturing. Dated by 2026-08-10, when the print that had driven the tape since June cleared without a re-rate, and by the week of 2026-08-17: fresh clinical data on 08-20 plus Buy reiterations from Lake Street and William Blair (2026-08-20) and BTIG (2026-08-21) produced a 2026-08-21 close of $40.95 against $40.03 on 2026-08-14. Well known, still working — the shares are up 24.1% over three months — with the incremental headline bid reduced to a $30M bolt-on, a comfort study and maintained ratings.

Bullish and bearish views on Harrow, Inc.

The model's bull view on Harrow, Inc. (HROW), in brief: The sequential ramp is real in units. Q2 revenue $70.661M versus $44.2M in Q1 (+~60% QoQ, +11% YoY, 2026-08-10). VEVYE posted record quarterly revenue of $29.4M (+58% YoY); TRIESENCE 14,529 units (+162% YoY). The 2026-08-20 IHEEZO data addresses the exact use case driving unit… The bear view: The company missed its own floor. $70.661M against $71–81M guided (2026-08-10). Consensus at $70.342M had already drifted under the guidance midpoint, which is why the print moved little. The EBITDA guide requires a step no quarter has yet shown. H1 adjusted EBITDA was negative… Both cases follow in full.

Bull Case

• The sequential ramp is real in units. Q2 revenue $70.661M versus $44.2M in Q1 (+~60% QoQ, +11% YoY, 2026-08-10). VEVYE posted record quarterly revenue of $29.4M (+58% YoY); TRIESENCE 14,529 units (+162% YoY).
• The 2026-08-20 IHEEZO data addresses the exact use case driving unit growth. Retina practices repeat intravitreal injections over years; a statistically significant discomfort reduction (p≤0.048 at all four timepoints) gives the salesforce a controlled comparison against the incumbent topical anesthetic, alongside the BYOOVIZ/OPUVIZ push into the same offices.

• Sell-side coverage is uniformly constructive. Eight analysts, all Buy, consensus target $67.50 with a $59–$88 range (stockanalysis.com, 2026-08-23), versus the 2026-08-21 close of $40.95. BTIG's $63 target was reiterated on 2026-08-11.

Bear Case

• The company missed its own floor. $70.661M against $71–81M guided (2026-08-10). Consensus at $70.342M had already drifted under the guidance midpoint, which is why the print moved little.
• The EBITDA guide requires a step no quarter has yet shown. H1 adjusted EBITDA was negative in both quarters; the reaffirmed $80–100M annual range implies an H2 run-rate the business has not printed since Q2 2025's $17.0M.
• Margin is going the wrong way. Gross margin 71% in Q2 2026 versus 75% a year earlier, with the mix shifting toward biosimilars.
• The legacy leg is shrinking. ImprimisRx compounding revenue $14.6M in Q2 2026 versus $21.5M a year earlier, offsetting branded growth inside the consolidated line.
• Thin equity cushion. $14.8M of stockholders' equity against $292.4M loans payable net at 2026-06-30, with $30M of cash committed at the TYRVAYA close and H1 operating cash flow of $(18.7)M.
• Unanimous ratings are a positioning observable, not a support. With 8 of 8 covering analysts at Buy and the shares 25.3% below the $54.80 52-week high, revisions from here can only travel in one direction — an inference from the coverage distribution, not a forecast.

Setup & Price Structure

The 2026-08-21 close was $40.95, 25.3% under the $54.80 52-week high, with a three-month price change of +24.1% and RSI(14) at 59.6 — mid-range, neither washed out nor extended. The post-print behaviour is the structure that matters: the shares held the low-$40s through the 08-10 miss-versus-guide, the 08-20 clinical release and three Buy maintains, closing higher week-on-week ($40.03 on 2026-08-14 to $40.95 on 2026-08-21) without reclaiming anything near the high. That is consolidation, and it has been in place for roughly two weeks — too short a window to call a base formed.

Reference levels: $36 marks the floor of the post-Q2 stabilisation range; below it the mid-May reaction low near $34 becomes the next visible reference. On the upside there is no dated event to price against until the Q3 report.

Crowding evidence, stated as observables: all eight covering analysts carry Buy ratings with a $67.50 consensus target (2026-08-23); three of them reiterated inside 48 hours of the 08-20 data; the gap between that consensus and the $40.95 close is roughly 65%. No insider transactions have surfaced in the filings window since the print — a 2026-05-28 Benzinga piece flagged joint CEO/CFO buying earlier in the year, which is a headline about past filings and says nothing about current activity. No equity issuance or ATM drawdown has been disclosed since the 10-Q.

Catalyst Calendar (next 30 days)

• Nothing company-confirmed falls in the 2026-08-23 → 2026-09-22 window. No earnings date, no PDUFA, no announced conference presentation.
• ~2026-12-31 (est.) — TYRVAYA closing. Guided to H2 2026 with no date disclosed (2026-08-06). The first observable will be an 8-K; it triggers the $30M cash payment and starts consolidation of TYRVAYA revenue.
• ~2026-11-09 (est.) — Q3 2026 results. Not company-confirmed. First quarter of the H2 ramp the reaffirmed guide requires and the first full quarter of BYOOVIZ.

What Would Change Our Mind

The structure to watch is the low-$40s shelf that has absorbed the guidance miss, the clinical release and the ratings reiterations. Losing it takes the story back to the pre-print range: a weekly close below $36 erases the post-Q2 stabilisation and leaves the mid-May reaction low near $34 as the next reference. On the fundamentals, any cut to the $350–365M revenue or $80–100M adjusted EBITDA range at or before the Q3 report ends the reaffirmation as a support for the tape. A financing that arrives before the H2 ramp is visible — an equity offering, ATM drawdown or new debt in an 8-K or prospectus supplement — changes the leverage picture directly. And if the TYRVAYA close slips past year-end, the H2 guidance that assumed a contribution from it loses a piece.

The read improves on the reverse: a Q3 print showing the sequential revenue step the guide implies, with adjusted EBITDA positive by a meaningful margin, converts the arithmetic problem into a delivered ramp.

Correlation Notes

• Rate and credit sensitivity dominates the beta here. $292.4M loans payable net against $14.8M of equity makes the equity a residual claim on refinancing conditions; it will trade with small-cap credit spreads more than with drug-development sentiment.
• Not a clinical-stage comp. This is commercial ophthalmology specialty pharma (VEVYE, IHEEZO, TRIESENCE, VERKAZIA, plus BYOOVIZ/OPUVIZ biosimilars), so XBI-style binary-readout correlation is a poor frame; revenue is buy-and-bill and pharmacy-channel dependent.
• Physician-office reimbursement policy is a shared factor. IHEEZO and TRIESENCE revenue runs through in-office procedural economics; any change to that reimbursement framework hits the same line items that drove the Q2 unit records.
• Counterparty links. Viatris on TYRVAYA until the deal closes; Samsung Bioepis on BYOOVIZ and OPUVIZ supply. Both are external dependencies on revenue lines the FY guide leans on.
• Dry-eye competitive set. VEVYE and TYRVAYA both sell into a market with entrenched branded competition, so pricing news from that category reads across to Harrow's gross-to-net line.